Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S (LUN)

22
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in research, development, production, marketing and sale of pharmaceuticals for the treatment of diseases of the central nervous system

Lundbeck H AS is engaged in the research, development, manufacture and distribution of pharmaceuticals for brain disorders.

It focuses on the treatment of brain disorders such as Alzheimer's disease, epilepsy, Huntington's disease, mood disorders, Parkinson's disease, and psychosis.

The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
Sales per Businesses
20122013Delta
DKK (in Million)%DKK (in Million)%
Cipralex5,82739.4%5,93338.9% +1.79%
Ebixa2,80318.9%2,09613.7% -33.73%
Other Pharmaceuticals2,17414.7%1,83012% -18.8%
Azilect1,2248.3%1,3929.1% +12.07%
Xenazine1,1978.1%1,4209.3% +15.7%
Other Revenue626.004.2%1,4849.7% +57.82%
Lexapro575.003.9%---
Sabril376.002.5%530.003.5% +29.06%
Onfi--573.003.8%-
Sales per Regions
20122013Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe7,68751.9%7,02846.1% -9.38%
Rest of the World3,76825.5%4,07526.7% +7.53%
United States2,67418.1%2,63517.3% -1.48%
Denmark47.000.3%36.000.2% -30.56%
Officers and Executives
NameAgeOfficer SinceTitle
Ulf Arne Wiinberg56-President & Chief Executive Officer
Sven Håkan Björklund MD, PhD58-Chairman
Lars Bang52-SVP-Supply Operations & Engineering
Ole Chrintz--SVP-Commercial Operations & International Markets
Anders Götzsche47-Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen MD, PhD63-Executive Vice President-Research & Development
Thorleif Krarup62-Director
Jes Christian Wibroe Østergaard66-Director
Jørn Møller Mayntzhusen, MBA48-Director & Senior Manager-Supply Optimisation
Kim Rosenville Christensen55-Director & Synthesis Operator
Surperformance© rating of H. Lundbeck A/S
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Pharmaceuticals - Diversified
Shareholders
- Lundbeck Foundation 70,00%
- Investisseurs Institutionnels Européens 9,00%
- North American institutional investors 7,00%
- Danish private investors 6,00%
- Other shareholders 4,00%
- Investisseurs Institutionnels Danois 4,00%
Advertisement
Sector Pharmaceuticals - Diversified
Trading RatingInvestor Rating
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
Sector Pharmaceuticals - Diversified
Company contact information
9 Ottiliavej
DK 2500 Valby, Copenhagen
Denmark

Phone : +45 36 30 13 11
Fax : +45 36 30 19 40
Internet : http://www.lundbeck.com
Markets and indexes
- NASDAQ OMX nordic Kopenhagen
- Main Market Large
Stock Exchange Codes
- ISIN Code :  DK0010287234
- Bloomberg Code :  LUN:DC
- Reuters Code :  LUN.CO
- Datastream Code :  DK:LUND
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF